Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519428 · ClinicalTrials.gov registry record · Phase 4
Does Dual Therapy Hasten Antidepressant Response?
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 245
- Enrollment target
NCT00519428: Completed Phase 4 study, sponsored by New York State Psychiatric Institute.
NCT00519428 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 245 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00519428, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 245 participants
- Enrollment target
Study Summary
This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates than either monotherapy in 240 depressed subjects.
Primary Outcome
Life Table Survival Analysis run twice, once comparing Dual Therapy (i.e., Bupropion + Escitalopram) to Bupropion alone (i.e., Bupropion + Placebo) and once comparing Dual Therapy to Escitalopram alone (i.e., Escitalopram + Placebo). Because both analyses must significantly favor Dual Therapy, each individual analysis must reach a critical alpha = .0916 in order to reach an over-all alpha = .05.
Interventions
- DRUG escitalopram
- DRUG bupropion extra long (XL)
- DRUG escitalopram + bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
What the finished NCT00519428 record still lists
NCT00519428 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which escitalopram is the first listed.
NCT00519428 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00519428 about?
NCT00519428 is a clinical study titled "Does Dual Therapy Hasten Antidepressant Response?". This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates than either monotherapy in 240 depressed subjects.
What is the current status of trial NCT00519428?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 245 participants. The study started on 2007-08. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00519428?
The interventions under investigation include: escitalopram (DRUG), bupropion extra long (XL) (DRUG), escitalopram + bupropion (DRUG).
Who is sponsoring clinical trial NCT00519428?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00519428's enrollment target sits among peer trials
245 357th of 2000 higher than 1,644 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia